Hormonal
Multireceptor incretin agonists (targeting GLP-1, GIP, and/or Glucagon receptors) produce clinically meaningful weight loss by simultaneously suppressing appetite via central nervous system pathways and increasing energy expenditure via peripheral metabolic activation.
If you have obesity, relying on willpower and diet alone often fails because your body fights back by slowing your metabolism and increasing hunger. Modern incretin-based medications work by targeting specific hormone receptors to simultaneously turn off the drive to eat and turn up your energy expenditure. This dual approach addresses the physiological root of obesity, offering significantly higher weight loss potential than lifestyle changes alone, with newer formulations designed to minimize side effects like nausea.
Indeed, multireceptor agonists targeting the GLP-1, GIP, and glucagon receptors produce meaningful weight loss in people with obesity. ... activation of the GIP receptor in the brain and the glucagon receptor in the liver and adipose tissue functions to synergize with GLP-1 receptor agonism to curb the drive to feed and ignite the combustion of excess calories for providing next-generation weight loss.
Why this rating
The paper is a review citing multiple clinical trials and preclinical studies showing robust efficacy, though it does not present new primary data itself.
Source
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Ricardo J. Samms et al. · Annual Review of Physiology · 2024
DOI 10.1146/annurev-physiol-022724-105443
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →